|
|
 |
June 19, 2008 |
Now Available:
Watch video podcasts of the 2008 EULAR press conferences
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Report Coverage of the 2008 EULAR Congress:
Michael T. Nurmohamed, MD, PhD presents "Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis" at the 2008 EULAR Congress
EULAR 2008: Baminercept shows good safety, substantial activity against RA in phase II data reported at EULAR
Baminercept alfa, a novel lymphotoxin ¦Â-receptor blocker, showed promising safety and efficacy in phase II data reported at EULAR...
EULAR 2008: Infliximab (Remicade) Plus Combination DMARD Therapy for Early RA Increases Remission Rate, Slows Radiological Progression
Adding infliximab (INF) to effective combination DMARD therapy for patients with early RA both increases the remission and slows progression of joint damage...
EULAR 2008: Anti-TNF Gene Therapy Appears Safe, May Reduce Pain, Swelling in RA Joints
Researchers report that transferring a TNF-antagonist gene into the joint is safe, may reduce pain and swelling in patients with inflammatory arthritis...
Consumer News: Stem Cells Might Treat Tough Fractures
Adult stem cells may be the key to healing broken bones that fail to mend properly on their own...
New from PubMed: Influence of Musculoskeletal Conditions on Oral Health Among Older Adults
Several musculoskeletal diseases negatively influence oral health, but damage can be minimized with simple and inexpensive measures...
BioPharm Business: Rigel Launches Two Global Phase IIb Clinical Trials of Syk Inhibitor, R788 (fostamatinib disodium), in RA
Rigel currently has small-molecule product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma...
BioPharm Business: ChemoCentryx Completes Enrollment of Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN) in Crohn's; Reports Advancing Second-Generation CCR9 Drug
The trial comprises three discrete phases to evaluate the efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over 12 months...